Healthcare >> Analyst Interviews >> March 27, 2019
Scrutiny of Pharmacy Benefit Managers Resulting in Visibility of Drug Prices
Steve Brozak is Managing Partner and President of WBB Securities, LLC. Dr. Brozak leads WBB Securities, LLC, an investment bank and financial analytical firm engaged in the pharmaceutical, biotechnology and medical device sectors. He has actively followed the evolving health care space over the last two decades and has written about and advised both health care companies and U.S. government agencies. Dr. Brozak has also written several health-care-related commentaries, including “A 21st Century Nosocomial Issue with Endoscopes” published in the British Medical Journal. Additional commentaries written by Dr. Brozak include “Seeking Innovation: Incentive Funding for Biodefense Biotechs Biosecurity and Bioterrorism” in Biodefense Strategy, Practice, and Science; “Long Shadow of the Stem-Cell Ruling: The Bankers” in Nature; “Caution – FDA Could Be, Hazardous to our Health” in Food and Drug Law Journal; and “Fighting Epidemics With Venture Capital” on Bloomberg Government. Dr. Brozak is frequently quoted by major news organizations and has been an invited speaker at numerous industry gatherings. The Wall Street Journal named Dr. Brozak as the “Best on the Street” Financial Analyst for the medical equipment and supplies category in its 19th Annual Best on the Street survey. In 2013, Dr. Brozak was a top-ranked analyst in the pharmaceutical industry based on his 12-month performance returns by Thomson Reuters and StarMine, and is also a top-ranked biotech analyst. Dr. Brozak is a retired lieutenant colonel in the United States Marine Corps and served on the Secretary of the Navy’s Navy and Marine Corps Retiree Council, where he focused on health care. Dr. Brozak holds a B.A. and MBA from Columbia University and his Doctorate in Medical Humanities — DMH — from Drew University. Profile
Word count: 3,842
TWST: What is your general outlook on the biotech and pharma space for the rest of 2019?
Dr. Brozak: We are facing the most fluid health care,